Entrada Therapeutics, Inc. (TRDA) Tops Q1 EPS by 7c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q1 EPS of ($0.95), $0.07 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $875 thousand versus the consensus estimate of $3.34 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04
• GE Vernova wins stage 3 contract for Queensland battery project
• Jefferies: 38% of Australian companies beat estimates this season